Bryan Zweig, MD
Cardiovascular Disease · Detroit, MINPI 1124141254
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,840 of the $17,953 with a category attached, or 82.7%. Edwards Lifesciences accounts for 91.9% of it on its own, with 4 other manufacturers making up the rest.
Across 28 payments — averaging $641.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$16K
- Abbott$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$103
- Chiesi USA, Inc.$34
- Bridgebio Pharma, Inc.$26
Across 3 payments — averaging $27,269 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$82K
What the payments were for
- Consulting fees$14,84083%
- Travel & lodging$2,09512%
- Food & beverage$1,0186%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 16 | $16,490 |
| Abbott | 8 | $1,300 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $103 |
| Chiesi USA, Inc. | 2 | $34 |
| Bridgebio Pharma, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,953 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 204 | $249,596 |
| XareltoRivaroxaban | 20 | $25,498 |
| OzempicSemaglutide | 17 | $15,454 |
| Repatha SureclickEvolocumab | 13 | $12,729 |
| Icosapent Ethyl | 13 | $4,364 |
| Metoprolol Succinate | 251 | $4,233 |
| Atorvastatin Calcium | 163 | $2,977 |
| Losartan Potassium | 133 | $2,024 |
| Amiodarone Hcl | 25 | $1,662 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 39 | $1,459 |
| Spironolactone | 99 | $1,380 |
| Rosuvastatin Calcium | 81 | $1,338 |
| Carvedilol | 84 | $1,156 |
| Bumetanide | 23 | $925 |
| Nifedipine ErNifedipine | 33 | $918 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Detroit
- Pedro Villablanca SpinettoDetroit$620K
- Wayne WeaverDetroit$340K
- Brian OneillDetroit$250K
- Karthikeyan AnanthasubramaniamDetroit$112K
- Gerald KoenigDetroit$96K
- David LanfearDetroit$82K
- Celeste WilliamsDetroit$70K
- Mahir ElderDetroit$68K
- Cori RussellDetroit$67K
- Pedro Engel GonzalezDetroit$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.